By Barbara Obstoj-Cardwell. Editor
M&A news last week featured US pharma major Eli Lilly announcing a $3.2 billion bid to acquire gastroenterology specialist Morphic. On the research front, US clinical-stage biotech HilleVax announced disappointing Phase IIb results with its norovirus vaccine HIL-214. Also, Dutch firm uniQure pleased investors with early--stage results for its investigational Huntington’s disease drug AMT-130, and US pharma giant Pfizer announced it is progressing its Parkinson’s disease candidate danuglipron.
Morphic deal expands Lilly’s IBD pipeline
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze